Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632922 | 0.82 | GLA (0.49) | GLANPSR1BACE1DAOTAAR1 | |
| SCHEMBL16460894 | 0.82 | GLA (0.67) | GLANPSR1BACE1CES2MDM2 | |
| SCHEMBL12746561 | 0.81 | GLA (0.69) | GLANPSR1DAOMDM2 | |
| SCHEMBL9193771 | 0.80 | GLA (0.69) | GLANPSR1CES2IDO1MDM2 | |
| SCHEMBL15570301 | 0.79 | GLA (0.67) | GLANPSR1CES2HSD11B1MDM2 | |
| SCHEMBL15647719 | 0.79 | GLA (0.67) | GLANPSR1PPARGMDM2KMT2A | |
| SCHEMBL7417047 | 0.78 | GLA (0.66) | GLANPSR1CES2MDM2 | |
| SCHEMBL5639921 | 0.77 | BACE1 (0.61) | GLANPSR1BACE1DAOTAAR1 | |
| SCHEMBL9198230 | 0.76 | NPSR1 (0.63) | GLANPSR1MDM2KMT2A | |
| SCHEMBL9193307 | 0.76 | GLA (0.63) | GLANPSR1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555941-B2 | Alkyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-11 | — | — | US | disclosed |
| US-10555941-B2 | Alkyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-11 | — | — | US | disclosed |
| EP-3057421-B1 | ALKYL LINKED QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3560920-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF ROR GAMMA T | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3057949-B1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF ROR GAMMA T | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| US-20170258782-A1 | ALKYL LINKED QUINOLINYL MODULATORS OF RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | US | disclosed |
| US-20170258782-A1 | ALKYL LINKED QUINOLINYL MODULATORS OF RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | US | disclosed |
| US-20170258782-A1 | ALKYL LINKED QUINOLINYL MODULATORS OF RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | US | disclosed |
| EP-2909192-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2801570-A1 | Inhibitors of beta-secretase | Vitae Pharmaceuticals, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | GLA 46/4885NPSR1 2008/4885BACE1 1/4885 |
| US-20170258782-A1 | ALKYL LINKED QUINOLINYL MODULATORS OF RORγt | RORC, RORB, RORA | GLA 2435/4885NPSR1 160/4885BACE1 1723/4885 |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | GLA 2334/4885NPSR1 258/4885BACE1 2116/4885 |
| US-10555941-B2 | Alkyl linked quinolinyl modulators of RORγt | RORC, RORB, RORA | GLA 2435/4885NPSR1 160/4885BACE1 1723/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | GLA 46/4885NPSR1 2008/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.